JP5933164B2 - テルペン化合物を含む組成物及び神経伝達の抑制方法 - Google Patents

テルペン化合物を含む組成物及び神経伝達の抑制方法 Download PDF

Info

Publication number
JP5933164B2
JP5933164B2 JP2009548553A JP2009548553A JP5933164B2 JP 5933164 B2 JP5933164 B2 JP 5933164B2 JP 2009548553 A JP2009548553 A JP 2009548553A JP 2009548553 A JP2009548553 A JP 2009548553A JP 5933164 B2 JP5933164 B2 JP 5933164B2
Authority
JP
Japan
Prior art keywords
composition
pain
neuropathic pain
geraniol
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009548553A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010518030A (ja
JP2010518030A5 (enExample
Inventor
アレクサンダー マクラーレン
アレクサンダー マクラーレン
フランク グリーンウェイ
フランク グリーンウェイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Louisiana State University
Original Assignee
Louisiana State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Louisiana State University filed Critical Louisiana State University
Publication of JP2010518030A publication Critical patent/JP2010518030A/ja
Publication of JP2010518030A5 publication Critical patent/JP2010518030A5/ja
Application granted granted Critical
Publication of JP5933164B2 publication Critical patent/JP5933164B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
JP2009548553A 2007-02-06 2008-02-06 テルペン化合物を含む組成物及び神経伝達の抑制方法 Expired - Fee Related JP5933164B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89964207P 2007-02-06 2007-02-06
US60/899,642 2007-02-06
PCT/CA2008/000236 WO2008095297A1 (en) 2007-02-06 2008-02-06 Composition comprising terpene compounds and methods for inhibiting nerve transmission

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016013591A Division JP6144785B2 (ja) 2007-02-06 2016-01-27 神経障害性疼痛を治療するための組成物

Publications (3)

Publication Number Publication Date
JP2010518030A JP2010518030A (ja) 2010-05-27
JP2010518030A5 JP2010518030A5 (enExample) 2011-03-17
JP5933164B2 true JP5933164B2 (ja) 2016-06-08

Family

ID=39681217

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009548553A Expired - Fee Related JP5933164B2 (ja) 2007-02-06 2008-02-06 テルペン化合物を含む組成物及び神経伝達の抑制方法
JP2016013591A Expired - Fee Related JP6144785B2 (ja) 2007-02-06 2016-01-27 神経障害性疼痛を治療するための組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016013591A Expired - Fee Related JP6144785B2 (ja) 2007-02-06 2016-01-27 神経障害性疼痛を治療するための組成物

Country Status (9)

Country Link
US (2) US9999601B2 (enExample)
EP (1) EP2142182B1 (enExample)
JP (2) JP5933164B2 (enExample)
KR (2) KR20150046328A (enExample)
CN (2) CN105581999A (enExample)
AU (1) AU2008213772A1 (enExample)
CA (1) CA2676139C (enExample)
HK (1) HK1224231A1 (enExample)
WO (1) WO2008095297A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016121169A (ja) * 2007-02-06 2016-07-07 ニューロクエスト インク 神経障害性疼痛を治療するための組成物

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008112641A2 (en) 2007-03-09 2008-09-18 New York University Methods and compositions for treating thalamocortical dysrhythmia
CA2732784C (en) * 2008-08-13 2018-09-18 Neuroquest Inc. Compositions comprising terpene compounds for treating negative sensory phenomena
CA2811241A1 (en) * 2010-09-14 2012-03-22 Neuroquest Inc. Terpenoid analogues and uses thereof for treating neurological conditions
WO2012053003A1 (en) * 2010-10-18 2012-04-26 Anil Kumar Gupta A novel herbal oil for controlling blood sugar without risk of hypoglycemea
CA2841972A1 (en) * 2011-07-14 2013-01-17 Neuroquest Inc. Terpene analogues and uses thereof for treating neurological conditions
US9228727B2 (en) 2012-04-05 2016-01-05 Michael W. May Lighting assembly
WO2013168090A1 (en) 2012-05-07 2013-11-14 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Researc Organization (Aro) (Volcanii Center). Geranium oil and constituents thereof for treatment of neurodegenerative diseases
WO2014051113A1 (ja) 2012-09-28 2014-04-03 株式会社資生堂 Ｖｅｇｆｃ産生促進剤
WO2014187946A1 (en) * 2013-05-24 2014-11-27 Nestec S.A. Treatment or prevention of autism disorders using menthol, linalool and/or icilin
US10493042B2 (en) 2013-08-01 2019-12-03 University-Industry Cooperation Group Of Kyung Hee University Method for preventing or treating diabetes mellitus, and method for screening for diabetes mellitus therapeutic agent
WO2015016682A1 (ko) 2013-08-01 2015-02-05 경희대학교 산학협력단 당뇨병 예방 또는 치료용 약학적 조성물, 당뇨병 예방 또는 치료 방법, 및 당뇨병 치료제 스크리닝 방법
KR102250582B1 (ko) 2018-05-11 2021-05-12 고려대학교 산학협력단 별아교세포 특이적 수동전도도 억제약물의 스크리닝 시스템 및 이의 활용

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1555333A (en) 1975-05-29 1979-11-07 Bush Boake Allen Ltd Perfumery compositions comprising hydroxy- or alkoxy-substituted c9 alkanals alkanols and esters
NZ190416A (en) 1978-05-16 1981-05-29 Unilever Ltd Deodorant product
CH673931A5 (enExample) 1986-05-08 1990-04-30 R & C Products Pty Ltd
DE3779500T2 (de) 1986-06-10 1993-01-21 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
DE3725248A1 (de) 1987-07-30 1989-02-09 Henkel Kgaa Antimikrobiell wirksame, aromatisierte zubereitungen
US5770738A (en) 1992-03-05 1998-06-23 Boehringer Ingelheim Kg Esters of bi- and tricyclic amino alcohols, their preparation and their use in pharmaceutical compositions
US5260313A (en) * 1992-03-12 1993-11-09 National Pain Institute, Inc. Diagnosis and treatment of various neuralgias
US6248307B1 (en) 1999-04-14 2001-06-19 Standard Homeopathic Company Compositions and treatment for alleviation of symptoms associated with menopause
EP1424071B1 (en) 2001-08-08 2008-08-20 Shiseido Company Limited Perfume compositions
US20030092636A1 (en) 2001-11-06 2003-05-15 Silberstein Stephen D. Treatment and prevention of paresthesia comprising co-therapy with anticonvulsant derivatives and potassium
AU2002360517A1 (en) * 2001-12-07 2003-06-23 Ximed Group Plc Respiratory infection prevention and treatment with terpene-containing compositions
US20030224072A1 (en) * 2002-06-03 2003-12-04 Frome Bruce Marshall Topical and oral administration of a composition containing Pelargonium Graveolens for diagnosis and treatment of various neuralgias and other conditions
US7943166B2 (en) * 2003-04-10 2011-05-17 Neurogesx, Inc. Methods and compositions for administration of TRPV1 agonists
US20050025823A1 (en) * 2003-07-29 2005-02-03 Fong Andy A.T. Methods of use of herbal compositions
US20050112183A1 (en) 2003-11-25 2005-05-26 Galer Bradley S. Compositions and methods for treating neuropathic sensory loss
US20060004050A1 (en) 2004-07-02 2006-01-05 Speicher Brian T Compositions and methods for the prevention or treatment of pain and other nervous system disorders
WO2006105481A1 (en) * 2005-03-30 2006-10-05 Neurogesx, Inc. Low-concentration capsaicin patch and methods for treating neuropathic pain
US20070203080A1 (en) 2006-02-15 2007-08-30 The Regents Of The University Of California New Drug Delivery System for Crossing the Blood Brain Barrier
WO2008108825A2 (en) 2006-10-10 2008-09-12 Burnham Institute For Medical Research Neuroprotective compositions and methods
KR20090082507A (ko) * 2006-11-20 2009-07-30 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 통증 및 소양증 치료용 방법, 조성물 및 키트
CN105581999A (zh) * 2007-02-06 2016-05-18 安元有限公司 用于抑制神经传导的包括萜烯化合物的组合物以及方法
US8236239B2 (en) 2007-11-16 2012-08-07 Bernstein Eric F Sterilizing compositions comprising phosphors for converting electromagnetic radiation to UVC radiation and methods for using the same
GB2460214A (en) 2008-03-20 2009-11-25 Hexcel Composites Ltd Prepregs for use in making laminates of reduced porosity
FR2934925B1 (fr) * 2008-08-06 2011-02-25 Soitec Silicon On Insulator Procede de fabrication d'une structure comprernant une etape d'implantations d'ions pour stabiliser l'interface de collage.
CA2732784C (en) 2008-08-13 2018-09-18 Neuroquest Inc. Compositions comprising terpene compounds for treating negative sensory phenomena
WO2010057295A1 (en) 2008-11-18 2010-05-27 Origin Biomed Inc. Homeopathic composition comprising hypericum perforatum extract and essential oils for the treatment of neuropathic pain
CA2811241A1 (en) 2010-09-14 2012-03-22 Neuroquest Inc. Terpenoid analogues and uses thereof for treating neurological conditions
CA2841972A1 (en) 2011-07-14 2013-01-17 Neuroquest Inc. Terpene analogues and uses thereof for treating neurological conditions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016121169A (ja) * 2007-02-06 2016-07-07 ニューロクエスト インク 神経障害性疼痛を治療するための組成物

Also Published As

Publication number Publication date
CN105581999A (zh) 2016-05-18
WO2008095297A1 (en) 2008-08-14
HK1224231A1 (zh) 2017-08-18
JP2016121169A (ja) 2016-07-07
AU2008213772A1 (en) 2008-08-14
KR20100014922A (ko) 2010-02-11
US9999601B2 (en) 2018-06-19
JP2010518030A (ja) 2010-05-27
EP2142182A4 (en) 2010-03-03
CA2676139A1 (en) 2008-08-14
US20180207110A1 (en) 2018-07-26
JP6144785B2 (ja) 2017-06-07
EP2142182A1 (en) 2010-01-13
CN101677973A (zh) 2010-03-24
EP2142182B1 (en) 2017-09-27
KR20150046328A (ko) 2015-04-29
KR101580857B1 (ko) 2015-12-30
CA2676139C (en) 2016-04-26
US20110257255A1 (en) 2011-10-20

Similar Documents

Publication Publication Date Title
JP6144785B2 (ja) 神経障害性疼痛を治療するための組成物
Cioanca et al. Inhalation of coriander volatile oil increased anxiolytic–antidepressant-like behaviors and decreased oxidative status in beta-amyloid (1–42) rat model of Alzheimer's disease
US20240050454A1 (en) Compositions and Methods For Treating Neurological Conditions
US20160317466A1 (en) Compositions comprising terpene compounds for treating negative sensory phenomena
Venâncio et al. Ocimum basilicum leaf essential oil and (-)-linalool reduce orofacial nociception in rodents: a behavioral and electrophysiological approach
US20180055903A1 (en) Homeopathic composition comprising hypericum perforatum extract and essential oils for the treatment of neuropathic pain
Melo et al. (−)-α-Bisabolol reduces orofacial nociceptive behavior in rodents
CA2431795A1 (en) Topical and oral administration of a composition containing pelargonium graveolens for diagnosis and treatment of various neuralgias and other conditions
Zhou et al. Borneol’s Pre-Clinical Analgesic Efficacy: Mediated by Receptor and Immune Mechanisms
El-Nabtity et al. Anticonvulsant activity of hydroalcoholic Phoenix dactylifera fruit extract and Pimpinella anisum oil in mice
CA2788493A1 (en) Composition and method for the treatment of neuropathic pain
Huntsman et al. Cannabis for pediatric and adult epilepsy
JP2017036228A (ja) 内服用組成物
McLellan et al. Compositions comprising terpene compounds for treating negative sensory phenomena
Sharma et al. Amine precursors in depressive disorders and the blood-brain barrier
Hayta et al. Neuroprotective effects of Sideritis trojana essential oil in AlCl3-induced amnesic rats
Faisal et al. Iraqi Journal of Pharmacy
EMBLICA et al. THE TAMILNADU Dr. MGR MEDICAL UNIVERSITY, CHENNAI. TAMILNADU
FR3108036A1 (fr) Composition pharmaceutique ou diététique contenant l’extrait aqueux de la lavande et utilisable comme antidiabétique

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110127

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20120413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120413

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130411

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130418

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130521

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130704

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130731

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140328

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140421

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20140606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151022

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160129

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160502

R150 Certificate of patent or registration of utility model

Ref document number: 5933164

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees